Table 1 Mean age of main studies in HF management
Clinical studies | Ages of placebo Group (years old) | Ages of studied drug group (years old) |
|---|---|---|
HF subgroup of Hyvet (hypertension study) | 83.5 ± 3.1 | 83.6 ± 3.2 |
Seniors | 76.1 ± 4.8 | 76.1 ± 4.8 |
Charm-Alternative | 66.8 ± 10.5 | 66.3 ± 11 |
Merit HF | 63.7 | 63.9 |
Charm-Added | 64.1 ± 11.3 | 64.0 ± 10.7 |
Consensus | 71 | |
Solvd | 59.1 | 59.1 |
Cibis II | 61 | 61 |
Emphasis-HF | 68.6 ± 7.6 | 68.7 ± 7.7 |
Ephesus | 66 ± 12 | 64 ± 11 |
Rales | 65 ± 12 | 65 ± 12 |
Atlas study | Low-dose of lisinopril: 63.6 ± 10.3 | High-dose of lisinopril: 63.6 ± 10.5 |
Elite-1 trial | Losartan: 74(5-8) | Captopril: 73 (6-1) |
Elite-II trial | Losartan: 71.4 (6-7) | Captopril: 71 (6-9) |
Shift | 60.1 ± 11.5 | 60.7 ± 11.2 |
Copernicus | 63.4 ± 11.5 | 63.2 ± 11.4 |
Valiant | Captopril: 64.9 ± 11.8 Valsartan: 65 ± 11.8 | Valsartan + Captopril: 64.6 ± 11.9 |
Dig | 63.9 ± 11.7 | 63.8 ± 11 |